We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Researchers from Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have devised an oral insulin delivery approach that can potentially eliminate the need for daily injections for type 1 diabetics.
AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors.
The research team expects that the release of this device will offer diabetics a pain-free way to measure their glucose levels with the blink of an eye.
It is now possible to reprogram cells from the liver into the precursor cells that give rise to the pancreas by altering the activity of a single gene.